Dual inhibitor AEE788 reduces tumor growth in preclinical models of medulloblastoma

Translational Oncology

Volumn 3, Issue 5, 2010, Pages 326-335

  Meco, Daniela ^a   Servidei, Tiziana ^a   Zannoni, Gian Franco ^b   Martinelli, Enrica ^a   Prisco, Maria Grazia ^a   de Waure, Chiara ^a   Riccardi, Riccardo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CARBOPLATIN; CD31 ANTIGEN; CISPLATIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ETOPOSIDE; NEU DIFFERENTIATION FACTOR; PROTEIN KINASE B; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CELL LINE; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG INHIBITION; ENDOTHELIUM CELL; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MEDULLOBLASTOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 78449260118     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.10163     Document Type: Article

References (33)

1. Wechsler-Reya R and Scott MP (2001). The developmental biology of braintumors. Annu Rev Neurosci 24, 385-428.
2. Gilbertson RJ (2004). Medulloblastoma: signalling a change in treatment. Lancet Oncol 5, 209-218.
3. Faivre S, Djelloul S, and Raymond E (2006). New paradigms in anticancer therapy:targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 33, 407-420.
4. Hynes NE and Lane HA (2005). ERBB receptors and cancer: the complexity oftargeted inhibitors. Nat Rev Cancer 5, 341-354.
5. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, and Batchelor TT (2007). Angiogenesis in brain tumours. Nat Rev Neurosci 8, 610-622.
6. Ferrara N, Gerber HP, and LeCouter J (2003). The biology of VEGF and itsreceptors. Nat Med 9, 669-676.
7. Goldman CK, Kim J, Wong WL, King V, Brock T, and Gillepsie GY (1993). Epidermal growth factor stimulates vascular endothelial growth factor productionby human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4, 121-133.
8. Klos KS, Wyszomierski SL, Sun M, Tan M, Zhou X, Li P, Yang W, Yin G, Hittelman WN, and Yu D (2006). ErbB2 increases vascular endothelial growthfactor protein synthesis via activation of mammalian target of rapamycin/p70S6Kleading to increased angiogenesis and spontaneous metastasis of human breastcancer cells. Cancer Res 66, 2028-2037.
9. Yang W, Klos K, Yang Y, Smith TL, Shi D, and Yu D (2002). ErbB2 overexpressioncorrelates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer 94, 2855-2861.
10. Tortora G, Ciardiello F, and Gasparini G (2008). Combined targeting of EGFRdependentand VEGF-dependent pathways: rationale, preclinical studies andclinical applications. Nat Clin Pract Oncol 5, 521-530.
11. Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, et al. (2004). AEE788: a dual family epidermalgrowth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosinekinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 64,4931-4941.
12. Younes MN, Yazici YD, Kim S, Jasser SA, El-Naggar AK, and Myers JN (2006). Dual epidermal growth factor receptor and vascular endothelial growth factorreceptor inhibition with NVP-AEE788 for the treatment of aggressive follicularthyroid cancer. Clin Cancer Res 12, 3425-3434.
13. Yokoi K, ThaKer PH, Yazici S, Rebhun RR, Nam DH, He J, Kim SJ, Abbruzzese JL, Hamilton SR, and Fidler IJ (2005). Dual inhibition of epidermalgrowth factor receptor and vascular endothelial growth factor receptor phosphorylationby AEE788 reduces growth and metastasis of human colon carcinoma in anorthotopic nude mouse model. Cancer Res 65, 3716-3725.
14. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, et al. (2007). A perivascular niche for braintumor stem cells. Cancer Cell 11, 69-82.
15. Gajjar A, Hernan R, Kocak M, Fuller C, Lee Y, McKinnon PJ, Wallace D, Lau C, Chintagumpala M, Ashley DM, et al. (2004). Clinical, histopathologic, andmolecular markers of prognosis: toward a new disease risk stratification systemfor medulloblastoma. J Clin Oncol 22, 984-993.
16. Slongo ML, Molena B, Brunati AM, Frasson M, Gardiman M, Carli M, Perilongo G, Rosolen A, and Onisto M (2007). Functional VEGF and VEGF receptors areexpressed in human medulloblastomas. Neuro Oncol 9, 384-392.
17. Meco D, Servidei T, Riccardi A, Ferlini C, Cusano G, Zannoni GF, Giangaspero F, and Riccardi R (2009). Antitumor effect in medulloblastoma cells by gefitinib: ectopic HER2 overexpression enhances gefitinib effects in vivo. Neuro Oncol 11, 250-259.
18. Knizetova P, Ehrmann J, Hlobilkova A, Vancova I, Kalita O, Kolar Z, and Bartek J (2008). Autocrine regulation of glioblastoma cell cycle progression, viabilityand radioresistance through the VEGF-VEGFR2 (KDR) interplay. Cell Cycle 7, 2553-2561.
19. Gilbertson RJ, Clifford SC, MacMeekin W, Meekin W, Wright C, Perry RH, Kelly P, Pearson AD, and Lunec J (1998). Expression of the ErbB-neuregulinsignaling network during human cerebellar development: implications for thebiology of medulloblastoma. Cancer Res 58, 3932-3941.
20. Zannoni GF, Vellone VG, and Carbone A (2008). Morphological effects ofradiochemotherapy on cervical carcinoma: a morphological study of 50 cases ofhysterectomy specimens after neoadjuvant treatment. Int J Gynecol Pathol 27,274-281.
21. Younes MN, Park YW, Yazici YD, Gu M, Santillan AA, Nong X, Kim S, Jasser SA, El-Naggar AK, and Myers JN (2006). Concomitant inhibition of epidermalgrowth factor and vascular endothelial growth factor receptor tyrosine kinases reducesgrowth and metastasis of human salivary adenoid cystic carcinoma in anorthotopic nude mouse model. Mol Cancer Ther 5, 2696-2705.
22. Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, Reese ED, Conrad CA, Traxler P, Lane HA, et al. (2005). Combination therapyof inhibitors of epidermal growth factor receptor/vascular endothelial growth factorreceptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offersimproved glioblastoma tumor growth inhibition. Mol Cancer Ther 4, 101-112.
23. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J, and Fan Z (2003). HER2/PI-3K/Akt activation leads to a multidrugresistance in human breast adenocarcinoma cells. Oncogene 22, 3205-3212.
24. Servidei T, Riccardi A, Ferlini C, Ferlini C, and Riccardi R (2008). Chemoresistanttumor cell lines display altered epidermal growth factor receptor and HER3 signalingand enhanced sensitivity to gefitinib. Int J Cancer 123, 2939-2949.
25. Graus-Porta D, Beerli RR, Daly JM, and Hynes NE (1997). ErbB-2, the preferredheterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16, 1647-1655.
26. Campbell MR, Amin D, and Moasser MM (2010). HER3 comes of age: new insightsinto its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res 16, 1373-1383.
27. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, Sliwkowski MX, and Stern HM (2009). A central role for HER3 in HER2-amplified breastcancer: implications for targeted therapy. Cancer Res 68, 5878-5887.
28. Junttila TT, Akita RW, Parson K, Fields C, Lewis Phillips PC, Friedman LS, Sampath D, and Sliwkowski MX (2009). Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15, 429-440.
29. Hickinson DM, Klinowska T, Speake G, Vincent J, Trigwell C, Anderton J, Beck S, Marshall G, Davenport S, Callis R, et al. (2010). AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2(HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockadein cancer. Clin Cancer Res 16, 1159-1169.
30. Semenza GL (2003). Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3,721-732.
31. Keefe SM, Cohen MA, and Brose MS (2010). Targeting vascular endothelialgrowth factor receptor in thyroid cancer: the intracellular and extracellular implications. Clin Cancer Res 16, 778-783.
32. Hicklin DJ and Ellis LM (2005). Role of the vascular endothelial growth factorpathway in tumor growth and angiogenesis. J Clin Oncol 23, 1011-1027.
33. Sikkema AH, Dicks SH, den Dunnen WF, ter Elst A, Scherpen FJ, Hoving EW, Ruijtenbeek R, Boender PJ, de Wijn R, Kamps WA, et al. (2009). Kinome profilingin pediatric brain tumors as a new approach for target discovery. Cancer Res 69,5987-5995.